Colchicine-Containing Nanoparticles Attenuates Acute Myocardial Infarction Injury by Inhibiting Inflammation
- 26 August 2021
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 36 (6) , 1075-1089
Abstract
Purpose Anti-inflammatory therapy is important for reducing myocardial injury after acute myocardial infarction (MI). New anti-inflammatory drugs and their mechanism are necessary to be explored to improve clinical efficacy. We aimed to improve the efficacy of colchicine on attenuating MI injury by nano-drug delivery systems and to investigate the mechanism of anti-inflammatory. Methods A colchicine-containing delivery system based on calcium carbonate nanoparticles (ColCaNPs) was synthesized. The protection against MI by ColCaNPs was evaluated using an in vivo rat model established by ligating the left anterior descending coronary artery. Macrophage polarization and the levels of inflammatory cytokines were determined using immunohistochemistry, Western blot, and ELISA analysis. Results ColCaNP treatment showed about a 45% reduction in myocardial infarct size and attenuating myocardial fibrosis compared with groups without drug intervention after MI. Furthermore, ColCaNPs significantly decreased the levels of CRP, TNF-α, and IL-1β in serum and the expression of proinflammatory cytokine in myocardial tissues after MI (p < 0.05). We also found that ColCaNPs notably restrained pyroptosis and inhibited inflammatory response by modulating on M1/M2 macrophage polarization and suppressing TLR4/NFκB/NLRP3 signal pathway. Conclusion Colchicine-containing nanoparticles can protect against MI injury in a clinically relevant rat model by reducing inflammation. In addition, calcium carbonate nanoparticles can increase the cardioprotective effects of colchicine.Keywords
Funding Information
- Tianjin Health and Family Planning Commission (1)
- Tianjin Research Program of Application Foundation and Advanced Technology of China (1)
- Key Technologies Research and Development Program (1)
- Fundamental Research Funds for the Central Universities (1)
This publication has 53 references indexed in Scilit:
- Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activationClinical Science, 2016
- The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular InteractionNanomedicine, 2016
- AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophagesAnnals of the Rheumatic Diseases, 2016
- Anti-Inflammatory Treatment With Colchicine in Acute Myocardial InfarctionCirculation, 2015
- Squamous Cell Carcinoma of the Oral Cavity in a Woman With a 9-Year History of Ovarian Cancer: Is Exposure to Pegylated Liposomal Doxorubicin a Factor?The Oncologist, 2014
- A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammationNature Communications, 2014
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Does long-term treatment with Doxil® predispose patients to oral cancer?International Journal of Clinical Oncology, 2012
- Vascular permeability, vascular hyperpermeability and angiogenesisAngiogenesis, 2008
- Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancerAnnals of Oncology, 2007